Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review.
Leporati R, Auclin É, Morchón D, Ferriol-Galmés M, Laguna JC, Gorria T, Teixidó C, Aranzazu Amores M, Ambrosini P, Isla D, Russo GL, Mezquita L. Leporati R, et al. Ther Adv Med Oncol. 2024 Dec 17;16:17588359241306940. doi: 10.1177/17588359241306940. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39697619 Free PMC article. Review.
Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases.
Ambrosini P, Miliziano D, Liberti GD, Lorenzini D, Marchesi S, Bassetti A, Tamborini E, Leporati R, Beninato T, Mazzeo L, Brambilla M, Ganzinelli M, Prelaj A, Proto C, Braud FG, Russo GL, Occhipinti M. Ambrosini P, et al. Among authors: leporati r. Clin Lung Cancer. 2024 Nov 25:S1525-7304(24)00256-0. doi: 10.1016/j.cllc.2024.11.012. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39665942 No abstract available.
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.
Gomez-Randulfe I, Silva Díaz S, Escriu C, Mohammed S, Shah R, Benitez Fuentes JD, Cox S, Monaca F, Bria E, García-Campelo MR, Crook B, Talbot T, Leporati R, Balachandran K, Newsom-Davis T, Hughes S, Cove-Smith L, Taylor P, Blackhall F, Califano R. Gomez-Randulfe I, et al. Among authors: leporati r. Ther Adv Med Oncol. 2024 Sep 19;16:17588359241272957. doi: 10.1177/17588359241272957. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39355343 Free PMC article.
Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481].
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Occhipinti M, et al. Among authors: leporati r. Crit Rev Oncol Hematol. 2024 Dec;204:104521. doi: 10.1016/j.critrevonc.2024.104521. Epub 2024 Sep 23. Crit Rev Oncol Hematol. 2024. PMID: 39317528 No abstract available.
Unleashing precision: A review of targeted approaches in pleural mesothelioma.
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, Viscardi G. Occhipinti M, et al. Among authors: leporati r. Crit Rev Oncol Hematol. 2024 Nov;203:104481. doi: 10.1016/j.critrevonc.2024.104481. Epub 2024 Aug 17. Crit Rev Oncol Hematol. 2024. PMID: 39159705 Free article. Review.
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
Angerilli V, Sabella G, Simbolo M, Lagano V, Centonze G, Gentili M, Mangogna A, Coppa J, Munari G, Businello G, Borga C, Schiavi F, Pusceddu S, Leporati R, Oldani S, Fassan M, Milione M. Angerilli V, et al. Among authors: leporati r. Br J Cancer. 2024 Jul;131(1):159-170. doi: 10.1038/s41416-024-02705-8. Epub 2024 May 10. Br J Cancer. 2024. PMID: 38729995 Free PMC article.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, Proto C, Brambilla M, Dumitrascu AD, Inno A, Signorelli D, Pizzutilo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G, Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, Beninato T, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Pruneri G, Lo Russo G, Genova C, Vingiani A. Prelaj A, et al. Among authors: leporati r. Clin Lung Cancer. 2024 Mar;25(2):190-195. doi: 10.1016/j.cllc.2023.12.012. Epub 2023 Dec 22. Clin Lung Cancer. 2024. PMID: 38262770 Free article.
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi CA, Guarneri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. Among authors: leporati r. Ther Adv Med Oncol. 2023 Dec 20;15:17588359231204857. doi: 10.1177/17588359231204857. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38130467 Free PMC article.
24 results